Novo Nordisk recruits 500 people for Alzheimer's trial
Alzheimer’s has been called the graveyard of the pharmaceutical industry, and many companies have failed within the indication. Still, signs indicate that Novo Nordisk has a chance of success with its GLP-1 approach, and Lundbeck’s head of R&D says there’s ”relatively strong reasoning behind it.”
BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The world’s biggest pharmaceutical firms have been trying for decades. Danish Lundbeck is having a go, and recently, Novo Nordisk threw its hat in the ring.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.